 Cidara Therapeutics, Inc. CDTX, a biotechnology company developing long-acting therapeutics to transform the standard of care for patients facing serious fungal or viral infections, today announced that it has been added to the Russell 3000 Index at the conclusion of the Russell indexes annual reconstitution, effective upon the U.S. market open today, June 29, 2020. Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. Russell indexes are part of FTSE Russell, a leading global index provider. 